Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Sab Biotherapeutics Inc WT (SABSW)

Sab Biotherapeutics Inc WT (SABSW)
0.0041 x 1200 0.1474 x 3
Pre-market by (Cboe BZX)
0.1474 +0.0674 (+84.25%) 01/16/25 [NASDAQ]
0.0041 x 1200 0.1474 x 3
Pre-market 0.1474 unch (unch) 13:30 ET
Quote Overview for Thu, Jan 16th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.1474
Day High
0.1474
Open 0.1474
Previous Close 0.0800 0.0800
Volume 200 200
Avg Vol 25,130 25,130
Stochastic %K 52.46% 52.46%
Weighted Alpha +10.54 +10.54
5-Day Change +0.0145 (+10.91%) +0.0145 (+10.91%)
52-Week Range 0.0100 - 0.1888 0.0100 - 0.1888
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 2,240 K
  • Annual Income, $ -42,190 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/11/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0383 +284.86%
on 12/18/24
Period Open: 0.0510
0.1500 -1.73%
on 01/08/25
+0.0964 (+189.02%)
since 12/16/24
3-Month
0.0383 +284.86%
on 12/18/24
Period Open: 0.0450
0.1500 -1.73%
on 01/08/25
+0.1024 (+227.56%)
since 10/16/24
52-Week
0.0100 +1,374.00%
on 05/14/24
Period Open: 0.0300
0.1888 -21.93%
on 02/20/24
+0.1174 (+391.33%)
since 01/12/24

Most Recent Stories

More News
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

SABSW : 0.1474 (+84.25%)
SABS : 3.56 (+2.30%)
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

SABSW : 0.1474 (+84.25%)
SABS : 3.56 (+2.30%)
SAB Biotherapeutics Provides Company Update for Q2 2022 Financial Results

Expects cash is sufficient to fund operations for the forward twelve months...

SABS : 3.56 (+2.30%)
SABSW : 0.1474 (+84.25%)
SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...

SABS : 3.56 (+2.30%)
SABSW : 0.1474 (+84.25%)
SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer

SIOUX FALLS, S.D., June 06, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...

SABS : 3.56 (+2.30%)
SABSW : 0.1474 (+84.25%)
SAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering Summit

In-person presentation titled ‘Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutics’ to take place on June 7 in Park City,...

SABS : 3.56 (+2.30%)
SABSW : 0.1474 (+84.25%)
SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results

Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel...

SABS : 3.56 (+2.30%)
SABSW : 0.1474 (+84.25%)
SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference

SIOUX FALLS, S.D., May 12, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), announced today its participation at the H.C. Wainwright Global...

SABSW : 0.1474 (+84.25%)
SABS : 3.56 (+2.30%)
SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors

SIOUX FALLS, S.D., April 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...

SABS : 3.56 (+2.30%)
SABSW : 0.1474 (+84.25%)
SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results

SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised...

SABS : 3.56 (+2.30%)
SABSW : 0.1474 (+84.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Master Swing Trading: Strategies for Momentum and Trends